Lobbying disclosures · Lobbying report
REGN: second_quarter 2026 lobbying report
Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space. Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers. Intellectual property legislation related to biopharmaceutical manufacturers. Trade and tariff issues related to corporations. Tax and inflation issues related to corporations.
Follow REGN- Became public
- Jul 20, 2026, 8:34 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 3:58 PM EST
Why this is connected
Exact legal-name match: REGENERON PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/872589/).
Reported lobbying amounts
Expenses: $630,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/e66ffb43-8909-414c-b4e4-bab42e2065e1/","filing_uuid":"e66ffb43-8909-414c-b4e4-bab42e2065e1","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/e66ffb43-8909-414c-b4e4-bab42e2065e1/print/","filing_document_content_type":"text/html","income":null,"expenses":"630000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Maya J. Bermingham","dt_posted":"2026-07-20T20:34:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 OLD SAW MILL RIVER ROAD","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"TARRYTOWN","registrant_state":"NY","registrant_zip":"10591","registrant":{"id":401104131,"url":"https://lda.gov/api/v1/registrants/401104131/","house_registrant_id":null,"name":"REGENERON PHARMACEUTICALS, INC","description":"Biopharmaceutical development and manufacturing","address_1":"777 OLD SAW MILL RIVER ROAD","address_2":null,"address_3":null,"address_4":null,"city":"TARRYTOWN","state":"NY","state_display":"New York","zip":"10591","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MAYA J. BERMINGHAM","contact_telephone":"+1 914-598-3031","dt_updated":"2026-07-29T09:39:25.971423-04:00"},"client":{"id":200807,"url":"https://lda.gov/api/v1/clients/200807/","client_id":12,"name":"REGENERON PHARMACEUTICALS, INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-08-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Intellectual property legislation related to biopharmaceutical manufacturers.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Trade and tariff issues related to corporations.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax and inflation issues related to corporations.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140575,"prefix":null,"prefix_display":null,"first_name":"EBEN","nickname":null,"middle_name":null,"last_name":"DUROSS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71871,"prefix":null,"prefix_display":null,"first_name":"KATHERINE","nickname":null,"middle_name":null,"last_name":"HADDAD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140574,"prefix":null,"prefix_display":null,"first_name":"MADDIE","nickname":null,"middle_name":null,"last_name":"DAVIDSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in REGN
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
Bought Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 8, 2026$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Sold Regeneron Pharmaceuticals REGN
$1K–$15K · Traded May 15, 2026 · disclosed Jun 8, 2026
- May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Bought Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
- Mar 12, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Bought Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Feb 12, 2026 · disclosed Mar 12, 2026
- Feb 6, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
Sold Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Dec 15, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Bought Regeneron Pharmaceuticals REGN
$1K–$15K · Traded Nov 18, 2025 · disclosed Dec 15, 2025
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.